# Boston Scientific

> Boston Scientific is a VC fund backing Health Care and Medical Device. See 54 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Marlborough, United States
- Total investments: 54
- Last investment: May 2026
- Lead investor: 37%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/boston-scientific/
- X (Twitter): https://twitter.com/bostonsci
- Website: http://www.bostonscientific.com
- Facebook: https://www.facebook.com/BostonScientific

Boston Scientific is an innovator of medical solutions that improve the health of patients around the world. Boston Scientific's products and technologies are used to diagnose or treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health, and chronic pain conditions. BostonScientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies, and services across a wide range of medical specialties. These less-invasive medical technologies provide alternatives to major surgery and other medical procedures that are typically traumatic to the body. In less-invasive procedures, devices are usually inserted into the body through natural openings or small incisions and can be guided to most areas of the anatomy to diagnose and treat a wide range of medical problems. Boston Scientific continues to innovate in these areas and is extending its innovations into new geographies and high-growth adjacency markets. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Boston Scientific acts with integrity and compassion to support patients, customers, our communities, and each other.

## Contacts

5 contacts available for Boston Scientific. Shizune tracks 13 team members at Boston Scientific. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/boston-scientific?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $3M–$36M |
| Series C | $6M–$27M |
| Series D | $8.3M–$175M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 34 | 63% |
| Medical Device | 31 | 57% |
| Biotechnology | 19 | 35% |
| Medical | 14 | 26% |
| Therapeutics | 8 | 15% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 10 | 19% |
| Series C | 10 | 19% |
| Series D | 9 | 17% |
| Funding Round | 8 | 15% |
| Series A | 4 | 7% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 32 | 59% |
| Israel | 3 | 6% |
| Canada | 1 | 2% |
| Australia | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alexander Weir | Business Development Manager | 0 | https://shizune.co/investors/profile/alexander-weir |
| Douglas J. Duchon | Sr. Program Manager | 0 | https://shizune.co/investors/profile/douglas-j-duchon |
| Eric Thepaut | Executive Vice President, President EMEA | 0 | https://shizune.co/investors/profile/eric-thepaut |
| Ian T. Meredith | Executive Vice President and Global Chief Medical Officer | 0 | https://shizune.co/investors/profile/ian-t-meredith |
| Isaac Knoot | Vice President, US Sales Enablement | 0 | https://shizune.co/investors/profile/isaac-knoot |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MiRus | MiRus is a medical device company focused on designing innovative solutions for the treatment of spinal and orthopedic degeneration and deformities. | $1.5B | Corporate Round | May 18, 2026 |  |
| Anumana | Anumana develops AI algorithms that analyze ECG data to support early diagnosis of cardiovascular conditions. The company focuses on enhancing cardiac care through innovative technology, providing tools that assist healthcare professionals in identifying potential heart issues. Anumana's platform extends beyond diagnostics, aiming to improvepatient outcomes throughout the entire continuum of cardiovascular care, including perioperative and acute settings. By utilizing machine learning techniques, Anumana aims to refine screening processes, making it easier for clinicians to detect heart diseases and intervene promptly. This approach contributes to more efficient healthcare delivery and better management of cardiovascular health. |  | Series C | Apr 24, 2025 |  |
| 4C Medical Technologies | 4C Medical Technologies is a medical device company that develops minimally invasive therapies for structural heart disease. It preserves the native mitral valve and left ventricle, eliminating known issues associated with transcatheter mitral valve replacement technologies that rely on placement and fixation in the native mitral annulus and leftventricle. | $175M | Series D | Mar 05, 2025 |  |
| Nectero Medical | Nectero Medical develops a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms. The company was founded in 2017 and is headquartered in Dover, Delaware, United States. | $96M | Series D | Apr 11, 2024 |  |
| SetPoint Medical | SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $80M |  | Jan 19, 2023 |  |
| Nectero Medical | Nectero Medical develops a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms. The company was founded in 2017 and is headquartered in Dover, Delaware, United States. | $19.5M | Series C | Sep 10, 2021 |  |
| Append Medical | Append Medical develops a next-generation transcatheter Left Atrial Appendage (LAA) closure system.The Append Medical solution is in the pre-clinical in-vivo trial phase. It is intended to become a differentiated solution in the LAA closure market, which has been estimated to reach $25B within several years. This is the second-fastest growingsegment of the medical device market, with potential sales of $500M in 2019. Append Medical is a member of MEDX Xelerator, a medtech incubator backed by Boston Scientific, Intellectual Ventures, MEDX Ventures and Sheba Medical Center. | $7.4M | Series A | Aug 04, 2021 |  |
| SetPoint Medical | SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $64M |  | Jan 27, 2021 |  |
| Preventice Solutions | Preventice Solutions is a privately-held company that offers a portfolio of mobile cardiac health solutions and services. It is a developer of mobile health solutions and remote monitoring services, connecting patients, clinicians, and hospitals. | $137M | Series B | Jul 15, 2020 |  |
| SetPoint Medical | SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $15.7M |  | Sep 18, 2019 |  |

10 of 54 investments shown.

## Co-investors
- [Action Potential Venture Capital](https://shizune.co/investors/profile/action-potential-venture-capital) — VC Fund, 6 deals together
- [Morgenthaler Ventures](https://shizune.co/investors/profile/morgenthaler-ventures) — VC Fund, 6 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 5 deals together
- [Aperture Venture Partners](https://shizune.co/investors/profile/aperture-venture-partners) — VC Fund, 4 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 4 deals together
- [ONSET Ventures](https://shizune.co/investors/profile/onset-ventures) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [OurCrowd](https://shizune.co/investors/profile/ourcrowd) — VC Fund
- [Entrée Capital](https://shizune.co/investors/profile/entree-capital) — VC Fund
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in Israel](https://shizune.co/investors/health-care-vc-funds-israel)
- [Medical Device Investors in Middle East](https://shizune.co/investors/medical-device-investors-middle-east)
- [Medical Device VC Funds in Middle East](https://shizune.co/investors/medical-device-vc-funds-middle-east)
- [Medical Device Investors in Israel](https://shizune.co/investors/medical-device-investors-israel)
- [Medical Device VC Funds in Israel](https://shizune.co/investors/medical-device-vc-funds-israel)

## FAQ

### What does Boston Scientific invest in?

Boston Scientific invests primarily in Health Care, Medical Device and Biotechnology startups, most often at Series B and Series C stage. Most of the 54 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Boston Scientific's check size?

Boston Scientific typically joins rounds of $3M–$36M at Series B, $6M–$27M at Series C and $8.3M–$175M at Series D. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Boston Scientific participates in.

### How do I contact Boston Scientific?

Public channels for Boston Scientific include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Boston Scientific?

The team at Boston Scientific includes Alexander Weir (Business Development Manager), Douglas J. Duchon (Sr. Program Manager) and Eric Thepaut (Executive Vice President, President EMEA), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co